Yuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh

Similar documents
Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

This is a cross-sectional analysis of the National Health and Nutrition Examination

Asthma COPD Overlap (ACO)

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

Decramer 2014 a &b [21]

Lecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)

How to distinguish between uncontrolled and severe asthma

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD or not COPD, that is the question.

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Guideline for the Diagnosis and Management of COPD

PFT Interpretation and Reference Values

COPD: A Renewed Focus. Disclosures

N.G. Gorovenko, G.Y. Stupnytska, S.V. Podolskaya

Supplementary Online Content

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

Differential diagnosis

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

COPD: Current Medical Therapy

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

THE COPD-ASTHMA OVERLAP SYNDROME

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Basic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

COMORBIDITIES AS AN ELEMENT OF MULTIDIMENSIONAL PROGNOSTIC ASSESSMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Evaluation of Small Airways Disease in asthma medical research: Application of Structural Equation Modeling (SEM) and Latent Transition Analysis (LTA)

Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study

Known Allergies: Shellfish. Symptoms: abdominal pain, nausea, diarrhea, or vomiting. congestion, trouble breathing, or wheezing.

Is reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?

Heterogeneity of COPD and Asthma

RESPIRATORY CARE IN GENERAL PRACTICE

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Chronic Obstructive Pulmonary Disease (COPD).

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures

Bode index as a predictor of severity in patients with chronic obstructive pulmonary disease.

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08

Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli

Learning the Asthma Guidelines by Case Studies

Asthma and COPD. Health Net Provider Educational Webinar

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)

Potential risks of ICS use

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Chronic Obstructive Pulmonary Disease Guidelines and updates

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

Author's response to reviews

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D.

Referring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL

COPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS

S P I R O M E T R Y. Objectives. Objectives 3/12/2018

Supplementary Online Content

Dr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective

Advancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy

Global Initiative for Asthma (GINA) What s new in GINA 2017?

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

(2017), «EUREKA: Health Sciences» Number 6

What do pulmonary function tests tell you?

COPD. Helen Suen & Lexi Smith

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

Asthma ASTHMA. Current Strategies for Asthma and COPD

RESPIRATORY PHYSIOLOGY Pre-Lab Guide

ISSN: CODEN Code: PIHNBQ ZDB-Number: IC Journal No: Vol. 2 No Online Available at

COPD. Breathing Made Easier

COPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012

UNDERSTANDING COPD MEDIA BACKGROUNDER

Disclosure Statement. Epidemiological Data

Curriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital

Supplementary appendix

S P I R O M E T R Y. Objectives. Objectives 2/5/2019

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Do We Need Biologics in Pediatric Asthma Management?

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

The Aging Lung. Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI

Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD

Bronchodilator Effect of Tiotropium via Respimat Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):

Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)

Small Airways : How To Confident Diagnosis and Management?

Research in Real Life

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer

MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C

Accurately Measuring Airway Resistance in the PFT Lab

COPD: Applying New Guidelines to Optimizing Evaluation and Treatment

Update on Pulmonary Diseases. Jeffrey Lessar, MD

Transcription:

2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna Ksenia Nazarenko Svitlana Opimakh Factors of formation of small airways obstruction and lung hyperinflation in patients with combined pathology of asthma and chronic obstructive pulmonary disease Yuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh Abstract The most unfavorable variants of combined lung obstructive pathology are small airways obstruction and lung hyperinflation. The aim of this work was to study the factors of the formation of small airways obstruction and lung hyperinflation in patients with combined pathology of asthma and COPD. Severe violations of the lung function parameters in the form of small airways obstruction and pulmonary hyperinflation may exist simultaneously. The common factors of these complications are the elderly age of patients, bronchial obstruction, decreased exercise tolerance, severe dyspnea and high BODE index. The differences in risk factors are the dependence of small bronchial obstruction on the type of local bronchial inflammation and the disease from which the ACO debuted, while lungs hyperinflation depends on the factors of the general low health status and the decrease in the predicted life expectancy of the patients. Among the concomitant cardiovascular pathologies, arterial hypertension and the presence of left ventricular hypertrophy, along with obesity, have a greater effect on the obstruction of the distal respiratory tract, and ischemic heart disease - on lung hyperinflation. Pulmonary hypertension is a factor in the occurrence of both complications. Keywords: Asthma-COPD overlap, small airways obstruction, lung hyperinflation Introduction The combination of asthma and chronic obstructive pulmonary disease (asthma-copd overlap (ACO)) in one patient is an actual problem in pulmonology [1]. An interesting question is the pathophysiology of violations of the lung function parameters in ACO patients, and the choice of adequate therapy for these patients. The most unfavorable variants of these disorders are small airways obstruction and lung hyperinflation [2]. Factors contributing to the formation of these states are numerous and go beyond purely pulmonary pathology. According to literature, it is known that increased airiness of lung tissue on the one hand is more common in patients with concomitant cardiovascular pathology. On the other hand, lung hyperinflation promotes hemodynamic disorders by breaking the venous return and reducing the right ventricle preload, and large intrathoracic pressure causes left ventricular dysfunction [3]. There is also evidence that the formation of lung emphysema is associated with the neutrophilic type of bronchial inflammation [4]. The aim of this work was to study the factors of the formation of small airways obstruction and lung hyperinflation in patients with combined pathology of asthma and COPD. Correspondence Ksenia Nazarenko Materials and Methods The study included patients with ACO (n = 140) of an average age of 58.56 ± 0.81 years undergoing baseline therapy, but there were pronounced symptoms and impaired lung function. Diagnosis of ACO was exposed according to the criteria given in the main international guidelines for the management of asthma and COPD patients - GINA and GOLD [8, 9]. All patients had persistent, but variable symptoms characteristic of asthma and COPD, the state of patients was stable, no exacerbation 2 months before the study. The average forced expiratory volume for the first second (FEV1) of patients was (59.0 ± 1.4)% and the ratio of FEV1 to forced vital capacity (FVC) - FEV1 / FVC - (53.6 ± 0.8)%. In 91 patients, the disease debuted with asthma, in 49 other cases, a COPD was initially diagnosed. ~ 74 ~

Patients were on baseline asthma and COPD therapy according to the severity of the disease, all taking short-acting beta2 agonists (SABA) as needed, and drugs for disease control (inhaled corticosteroids (ICS), a combination of ICS/ long-acting beta agonists (LABA), Tiotropium bromide, or triple therapy - ICS/LABA/Tiotropium bromid). All patients underwent: general clinical examination, body mass and height measurements, body mass index (BMI), office systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse blood pressure (PBP) measurements, spirometry, whole body plethysmography and impulse oscillometry ("Master Screen Pneumo Cardinal Health (Germany)), FeNO measurement, ambulatory blood pressure monitoring (EC-3H/ABP (Labtech, Hungary)), echocardiography (VIVID E9, General Electric), Charlson comorbidity index assessment, COPD symptoms evaluation (CAT), asthma symptoms assessment (ACQ7 Questionnaire), mmrc-scale dyspnea assessment, BODE Index measurement [7], cardiovascular risk measurement (SCORE scale), 6- minutes walking test in accordance with the standard protocol [8]. Blood analysis was also performed and the serum creatinine level was determined. To assess the general probability of development of individual events under the influence of several risk factors, the Cochran-Mantel-Hensel criterion was used with the help of Review Manager software (RevMan 5.3) [9]. For the construction of a diagram illustrating the weight of the influence of the factors under study, the generator "DistillerSR Forest Plot Generator from Evidence Partners" [10] was used. In this case, the following reductions are applied: OR - odds ratio, LCL - lower confidence limit, UCL - upper confidence limit, WGHT - weight. Results and Discussion In studying the characteristics of the course of ACO with small airways obstruction, the criterion for distal respiratory tract obstruction was the parameter of impulse oscillometry R5-R20, which should not exceed 20% in healthy persons [11]. The OR of increasing the R5-R20 to 20% and more, as well as the weight of each individual factor was calculated (Figure 1). Fig 1: Risk factors of formation of small airways obstruction in patients with ACO The results show that the risk of small airways obstruction reliably depends on the patient's primary pathology. In this case, patients with an initial diagnosis of asthma have statistically significant chances to be protected from this course (odds ratio = 0, 27; 95% confidence interval from 0, 11 ~ 75 ~ to 0,65). Among other factors considered, the primary diagnosis of asthma is the most significant 18, 3%. The onset of COPD on the contrary more than three times increases the risk of small bronchial obstruction (odds ratio = 3, 67; 95% confidence interval from 1, 55 to 8, 72).

Regardless of the initial diagnosis, the risk of distal bronchial obstruction is increased with age (2, 16 times in patients older than 60 years of age). Among other general-clinical signs, obesity leads to small airway obstruction with a weight of factor of 7,5%, reduced tolerance to physical activity (the distance passed in a 6-minute walking test less than 300 meters leads to the probability of distal airways obstruction in the ratio of 3,77 to 1). The severity of the clinical course of the disease is also associated with the small airways obstruction, because with a dyspnea score of 2 and more (mmrc) it's risk increases in 2,92 times, and with a high BODE index ( 5 points) 6,39 times. The total weight of these two parameters among other factors is 9,9%. Functional markers of small bronchial obstruction are not only the decrease of FEV1 to the 30-50% (the risk of small airways obstruction in such conditions increases in 5, 21 times), but also the development of lung hyperinflation. With the increase of ITGV/TLC ratio up to 55% and more, the forecast for distal airway obstruction significantly decreases by 2, 3 times. The increase of the R5-R20 occurs simultaneously with other violations of the parameters of impulse oscillometry. The increase in the total resistance of the respiratory tract (R5 to 150% and above) and the resistance of the proximal airways (R20 to 150% and above), as well as an increase in AX above 3,37 and resonance frequency (Fres) above 12 Hz, increases the risk of distal obstruction at 26, 2, 12 and 6 times respectively. Concomitant cardiovascular pathology is an unfavorable factor in the course of ACO. An increase of PBP over 50 or 60 mm Hg increases the risk of small bronchial obstruction of 3,62 and 2,6 times respectively. Left ventricular hypertrophy is associated with an increase in the incidence of small bronchial obstruction in 2, 33, pulmonary hypertension - is 3- fold, a high SCORE index of 6 and more points - in 6,82 times. The mixed (eosinophilic-neutrophilic) type of local inflammation increases the risk of small airways obstruction in 5, 55 times. The factors of the development of lung hyperinflation in patients with ACO are clinical and functional features, as well as concomitant pathology (Figures 2 and 3). Fig 2: Risk factors for the formation of lungs hyperinflation in patients with ACO (increase of ITGV). Like the small airways obstruction, lung hyperinflation is formed under the influence of age (every decade of life "adds" 16% to this risk), as well as with the more severe course of ACO. In an uncontrolled course of asthma (ACQ>1, 5), in COPD with severe symptoms (over 20 points of CAT test), dyspnea score of 2 and more (mmrc scale), a high BODE index of 5, and decreased exercise tolerance (distance less than 300 meters in a 6-minute walk), the incidence of hyperinflation increases from 2,15 to 15,74 times. ~ 76 ~ Functional factors in the formation of excessive airiness of the lungs are the decrease of FEV1 below 80% (especially within 30-50%), the decrease in inspiratory capacity in the structure of the total capacity of the lungs (IC/TLC up to 25% and lower) and air trapping (increase of residual volume (RV) to 120% and higher). The presence of small bronchial obstruction (an increase in R5-R20 according to impulse oscillometry) increases the risk of pulmonary hyperinflation by 2, 31 times. Thus, pulmonary hyperinflation can exist simultaneously with small airways obstruction.

Fig 3: Risk Factors for the formation of lung hyperinflation in ACO patients (increase of ITGV/TLC) The presence of concomitant cardiovascular disease and general low level of health is very relevant in ACO patients. Thus, 10 years life expectancy less than 50% (Charlson comorbidity index) increases the risk of pulmonary hyperinflation by 3, 25 times with the factor of 8,2%, concomitant ischemic heart disease 2,7 times with a factor of 9,5% and pulmonary hypertension - in 2,81 times with a factor of 10,8%. The "non-dipping" status (ambulatory blood pressure monitoring) doubles the risk of lungs hyperinflation with a factor of 16, 2%. Such indicators of a general low health status with a reduced life expectancy as an increase of serum creatinine level above 115 μmol/l and a decrease in glomerular filtration rate below 60 ml/min associated with an increased risk of lung hyperinflation in 4,65 and 2,49 times, with a total weight of two factors of 13,5%. Thus, the assistance to ACO patients is not only in the pathogenetically justified purpose of anti-inflammatory and bronchodilator therapy, which will help prevent the formation of severe lung function disorders in the form of small airways obstruction and lung hyperinflation. Important is the question of timely detection and adequate treatment of concomitant pathology in this category of patients. Summary Severe violations of the lung function parameters in the form of small airways obstruction and pulmonary hyperinflation may exist simultaneously. The common factors of these ~ 77 ~ complications are the elderly age of patients, bronchial obstruction, especially FEV1 decrease below 50%, decreased exercise tolerance (distance in a 6-minute walking test less than 300 meters), severe dyspnea and high BODE index ( 5 points). The differences in risk factors are the dependence of small bronchial obstruction on the type of local bronchial inflammation and the disease from which the ACO debuted, while lungs hyperinflation depends on the factors of the general low health status and the decrease in the predicted life expectancy of the patients. Among the concomitant cardiovascular pathologies, arterial hypertension and the presence of left ventricular hypertrophy, along with obesity, have a greater effect on the obstruction of the distal respiratory tract, and ischemic heart disease - on lung hyperinflation. Pulmonary hypertension is a factor in the occurrence of both complications. References 1. Hines K, Peebles R. Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence. Curr Allergy Asthma Rep. 2017; 17:15. 2. Berge M. The Asthma COPD Overlap Syndrome: ACOS. Epidemiology and Historical Perspective. Tanaffos. 2017; 16:17. 3. Puente-Maestu L, Stringer W. Hyperinflation and its management in COPD. International Journal of COPD. 2006; 1:381-400.

4. Sharafkhaneh A, Hanania N, Kim V. Pathogenesis of Emphysema. Proc Am Thorac Soc. 2008; 5:475-477. 5. Global initiative for asthma, 2017. 6. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, 2017. 7. Celli B, Cote C, Marin J et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350:1005-1012. 8. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166:111-117. 9. RevMan 5. Cochraine community, 2017. [Web: http://community.cochrane.org/tools/review-productiontools/revman-5.] 10. Forest Plot Generator. Evidence partners, 2017. [Web:https://www.evidencepartners.com/resources/forest -plotgenerator/#forest_plot_9_graph_edit_linebyline.]bickel S, Popler J, Lesnick B et al. Impulse Oscillometry. Chest. 2014; 146:841-847. ~ 78 ~